← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV19행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))
PENG YUAN·Gastric Cancer (GC)
143 trials
Overview
Program
Iparomlimab and Tuvonralimab (QL1706)
Overview
Company
PENG YUAN
Overview
Modality
ANTIBODY
Overview
Target
Gastric Cancer (GC)
Overview
Indication
Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Biomarker
biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
PD
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
thrombocytopenia and grade 4 immune-mediated nephritis), so the maximum tolerated dose (MTD) was
Clinical
Safety signal
thrombocytopenia and grade 4 immune-mediated nephritis), so the maximum tolerated dose (MTD) was
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Iparomlimab and Tuvonralimab (QL1706) 비교 | 바이오정보모아